

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
30 January 2025 (30.01.2025)



(10) International Publication Number
WO 2025/021144 A1

(51) International Patent Classification:

C07K 19/00 (2006.01) *A61K 47/68* (2017.01)
A61K 38/21 (2006.01) *C07K 14/56* (2006.01)
A61K 47/64 (2017.01) *A61P 35/00* (2006.01)

(21) International Application Number:

PCT/CN2024/107511

(22) International Filing Date:

25 July 2024 (25.07.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2023/109070

25 July 2023 (25.07.2023)

CN

(71) Applicant: TJ BIOPHARMA (SHANGHAI) CO., LTD.

[CN/CN]; Rm802, 8F, 1Bld., West Tower, 88 Shangke Rd.,
Pudong New Area, Shanghai 201210 (CN).

(72) Inventors: CHEN, Xi; Rm802, 8F, 1Bld., West Tower, 88

Shangke Rd., Pudong New Area, Shanghai 201210 (CN).
LI, Xue; Rm802, 8F, 1Bld., West Tower, 88 Shangke Rd.,
Pudong New Area, Shanghai 201210 (CN). **QIANG, Min**;
Rm802, 8F, 1Bld., West Tower, 88 Shangke Rd., Pudong
New Area, Shanghai 201210 (CN). **ZHI, Li**; Rm802, 8F,
1Bld., West Tower, 88 Shangke Rd., Pudong New Area,
Shanghai 201210 (CN). **WANG, Zhengyi**; Rm802, 8F,
1Bld., West Tower, 88 Shangke Rd., Pudong New Area,
Shanghai 201210 (CN). **ZHENG, Xin**; Room 301, 3F,
1Bld., 20 Shengmingyuan Rd., Life Science Park, Chang-
ping District, Beijing 100000 (CN). **TIAN, Baihui**; Room
301, 3F, 1Bld., 20 Shengmingyuan Rd., Life Science Park,
Changping District, Beijing 100000 (CN). **ZHANG, Fei**;
Room 301, 3F, 1Bld., 20 Shengmingyuan Rd., Life Science
Park, Changping District, Beijing 100000 (CN). **YU, Qilin**;
Room C2001, 2nd Floor, Building 2, No. 1077 Zhangheng
Road, China (Shanghai) Pilot Free Trade Zone, Pudong
New Area, Shanghai 201203 (CN). **CHEN, Mingchen**;
Room 301, 3F, 1Bld., 20 Shengmingyuan Rd., Life Science
Park, Changping District, Beijing 100000 (CN). **LIU, Fan**;
Room 301, 3F, 1Bld., 20 Shengmingyuan Rd., Life Science
Park, Changping District, Beijing 100000 (CN).

(74) Agent: NTD UNIVATION INTELLECTUAL PROP-

ERTY AGENCY LTD., 10th Floor, Tower C, Beijing

Global Trade Center, 36 North Third Ring Road East,
Dongcheng District, Beijing 100013 (CN).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: MASKED INTERFERON FUSION PROTEINS AND USES THEREOF

(57) Abstract: Provided are masked interferon fusion proteins that is cleavable to release human type 1 interferon (IFN) polypeptide. In various examples, the masked interferon fusion proteins include a masking moiety, an IFN polypeptide, a cleavable linker connecting the masking moiety and the IFN polypeptide and an Ig Fc region that is linked to the IFN polypeptide. Methods of using the same for treating cancer and autoimmune disease or inflammatory condition are also provided. Also provided herein are interferon masking moieties that bind to human IFN and the uses for inhibiting IFN activity thereof.



WO 2025/021144 A1